No Data
Wedbush Maintains Passage Bio(PASG.US) With Buy Rating, Maintains Target Price $4
Optimistic Outlook for Passage Bio: Buy Rating Justified by Promising Clinical Results and Extended Cash Runway
Passage Bio Restructures and Extends Cash Runway
Express News | Passage Bio Says It Has Reviewed Its Operating Needs And Will Transition To An Outsourced Analytical Testing Model. This Transition, Coupled With An Associated Reduction In Workforce Of Approximately 55% And Reductions In Operating Expenses, Extends...
Passage Bio Reported Updated Data From The Ongoing Phase 1/2 UpliFT-D Trial Of PBFT02 For Frontotemporal Dementia With Granulin Mutations
Express News | Passage Bio : To Reduce Operating Costs and Better Align Its Workforce With Needs of Its Strategic Research and Development Strategy
